Houston, TX, United States of America

Michelle Han

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 9.2

ph-index = 3

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2018-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Journey of Michelle Han: Pioneering Solutions in Disease Treatment

Introduction: Michelle Han, a talented inventor hailing from Houston, TX, has made significant contributions to the field of medicine through her groundbreaking patents. With a total of 4 patents to her name, Han's work focuses on developing novel treatments for GLS1 mediated diseases, particularly cancer.

Latest Patents: Among her latest patents is the development of GLS1 inhibitors for treating disease. These compounds and compositions offer promising solutions in combating GLS1 mediated diseases, including cancer. Additionally, her work includes the creation of compounds that inhibit indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, paving the way for innovative therapeutic interventions.

Career Highlights: Michelle Han is a key figure at the University of Texas System, where she spearheads groundbreaking research initiatives. Her dedication to advancing medicine and improving patient outcomes has garnered recognition within the scientific community.

Collaborations: Han has had the privilege of collaborating with esteemed professionals such as Philip Jones and Alessia Petrocchi. Together, they work towards pushing the boundaries of medical innovation and driving forward progress in the field.

Conclusion: Michelle Han's unwavering commitment to innovation and her invaluable contributions to the field of medicine exemplify her as a trailblazer in disease treatment. Her patents serve as a testament to her dedication to improving healthcare practices and transforming the landscape of medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…